SEQUEL (COG0202) Study
SHINE (COG0201) Study
SHIMMER (COG1201) Study
START (COG0203) in Collaboration with the ACTC
Including Parkinson's disease and DLB
Lead Candidate: CT1812
Cognition has identified several compounds that bind to a receptor that regulates the cellular damage response and have shown potential in the treatment of neurodegenerative diseases. The company’s lead candidate, CT1812, is a first-in-class, orally dosed and highly brain penetrant small molecule that is being assessed as a treatment for mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies. Several studies designed to assess the safety, efficacy and mechanism of action of CT1812 are underway and planned.
Cognition has initiated plans to study CT1812 in indications beyond Alzheimer’s disease, including dry AMD.